Abstract
Subjects with type 2 diabetes experience an increased cardiovascular morbidity and mortality, related to a high prevalence of hypertension, dyslipidemia, and obesity. Antihypertensive treatment with beta-adrenergic receptor blockers may have deleterious metabolic consequences, including worsening of lipid profiles and insulin sensitivity. The centrally-acting sympatholytic agent moxonidine may improve these variables. In this randomised, double-blind multicenter study, the effects of two widely used antihypertensive agents--moxonidine (MOX) and the beta (1)-selective adrenergic receptor blocker metoprolol (MET)--on blood pressure and metabolic control were directly compared in hypertensive subjects with type 2 diabetes. Patients received either MOX (0.2 - 0.6 mg/d) or MET (50 - 150 mg/d) for 12 weeks, intending comparable blood pressure control. In total 200 patients were randomized. Here we report results from the per protocol population consisting of 127 patients (MOX 66, MET 61) but similar results were found in the ITT population. Reductions in systolic (SBP) and diastolic (DBP) blood pressures after 12 weeks were similar in both groups: In the MOX group, mean SBP (+/- SD) decreased from 154 +/- 12 to 142 +/- 17 mmHg and me...Continue Reading
Citations
Jan 18, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Rodney A VelliquettePaul Ernsberger
Jun 20, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Paul Ernsberger, Richard J Koletsky
Jun 27, 2007·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Matthias Weck
Feb 9, 2010·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Anna Masajtis-ZagajewskaMichał Nowicki
Feb 6, 2008·Diabetes, Obesity & Metabolism·D P MacfarlaneM Fisher
Nov 11, 2006·The Journal of Pharmacology and Experimental Therapeutics·Zheng Sun, Paul Ernsberger
Feb 23, 2012·Hypertension·Katie AyersNancy J Brown
Jan 14, 2010·Current Medical Research and Opinion·Vivian A Fonseca
Oct 9, 2013·Climacteric : the Journal of the International Menopause Society·S M KujalaR J Kaaja
Jul 23, 2013·Diabetes & Metabolism·P IyngkaranM C Thomas
Dec 23, 2004·Kidney International. Supplement·José AbellánJosé Luño
Jun 15, 2006·Mayo Clinic Proceedings·Craig S StumpJames R Sowers
Sep 3, 2011·Cardiovascular Therapeutics·Lincoln P EdwardsPaul Ernsberger
Mar 30, 2016·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Pyung Chun OhEak Kyun Shin
Mar 31, 2015·Open Heart·James J DiNicolantonioJames H O'Keefe
Dec 9, 2016·Metabolic Syndrome and Related Disorders·Vanessa EstatoEduardo Tibiriçá
Jan 31, 2008·The Journal of International Medical Research·H EbinçM Yilmaz
Nov 15, 2008·Journal of Hypertension·Maritta K Pöyhönen-AlhoRisto J Kaaja
Feb 10, 2006·Expert Review of Neurotherapeutics·V J Karthikeyan, Gregory Y H Lip
Oct 30, 2018·Current Drug Safety·Ahmad Abdulrahman AlmemanAhmad Hamad Aldosary
Dec 31, 2009·Omega·Rama RonenJanet K Long
Apr 7, 2006·Drugs·Caroline FentonKatherine A Lyseng-Williamson
Oct 14, 2020·Current Medical Research and Opinion·Markus P SchlaichAletta E Schutte
May 26, 2015·ACS Medicinal Chemistry Letters·Fabio Del BelloMaria Pigini